Functionalized lipid inactosomes to bind and clear SARS-CoV-2
Functionalized lipid inactosomes to bind and clear SARS-CoV-2
批准号:
10611896
负责人:
Daniel A Hammer
金额:
$20.31万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-04-20 至 2024-03-31
关键词:
2019-nCoVACE2AcuteAmino Acid MotifsAmino AcidsAntibodiesBacteriaBindingBiological AssayBiotechnologyCOVID-19Cell LineCell membraneCellsCessation of lifeChemicalsChemistryCholesterolCoculture TechniquesCoronavirusDevelopmentDiseaseDissociationEndocytosisEngineeringEpithelial CellsEpitheliumFamilyFat BodyFormulationFutureGenesHumanHybridsHydrophobicityIn VitroIncubatedInfectionInfectious AgentIntegral Membrane ProteinLecithinLengthLipidsMediatingMembraneMembrane LipidsMicellesMicrofluidic MicrochipsMicrofluidicsMolecularMolecular ConformationNanostructuresNaturePeptide HydrolasesPeptidesPhospholipidsPlantsProtein Binding DomainProteinsPulmonary Surfactant-Associated Protein ARecombinant ProteinsRecombinantsReporterRespiratory distressSARS coronavirusSARS-CoV-2 infectionSerine ProteaseSevere Acute Respiratory SyndromeStructureSurfaceSyndromeTMPRSS2 geneTertiary Protein StructureTestingTherapeuticVaccinesVariantVesicleViralVirionVirusVirus DiseasesWaterWorkWritingamphiphilicitybiosafety level 3 facilitydensitydesigndimerhydrophilicityinhibitorinnovationinterfacialmimeticsmonomernanobodiesnanoparticlenanovesiclenovelnovel coronaviruspandemic diseaseparticlepeptidomimeticsprecision medicinepreventprotein reconstitutionreceptorreceptor bindingreconstitutionrespiratoryself assemblysuccesssurfactantviral entry inhibitor
中文摘要
总结
英文摘要
Summary
Severe
respiratory
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of COVID-19, a world-wide
pandemic causing over 525K deaths in the U.S. and over 2.6M deaths world-wide as of this writing.
Here, we propose to make phospholipid vesicles and other related nanostructures (droplets and micelles) with
recombinant protein motifs that will bind and inactivate the SARS-CoV-2 virion – we call these structures
inactosomes. Our inactosomes will be novel hybrid materials into which functional recombinant proteins are
reconstituted. The functionalized protein will be variants of oleosin, a naturally occurring surfactant protein.
Previously, we have designed and produced novel oleosin variants that assemble into vesicle membranes and
micelles and can stabilize droplets due to their triblock-like free-chain amphiphilic structure. We can readily
incorporate functional peptide motifs into oleosin recombinantly.
SARS-CoV-2 can enter epithelial cells via endocytosis and/or fusion. Binding between the spike protein (S)
on SARS-CoV-2 and the ACE2 receptor is essential for the entry of the virus into the epithelium. The ACE2
receptor can mediate endocytosis. Alternatively, after binding to ACE2, a protease (TMPRSS2) can activate a
conformational change in the S protein leading to fusogenic entry. We envision a number of chemistries that will
be directly useful at interfering with infection by SARS-CoV-2. First, a family of spike protein binding motifs –
mini-proteins, single chain antibodies (sybodies), or ACE2 peptide mimetics - will be recombinantly added to the
hydrophilic ends of oleosin. These motifs have low dissociation constants with the spike protein receptor binding
domain and are much easier to produce than large antibodies. When these virus binding motif-oleosins are
reconstituted into nanostructures, the result will be a multivalent particle (inactosomes) that can bind directly to
SARS-CoV-2 and competitively blocks its entry. Next, we will incorporate an oleosin that presents a small
peptidic fusion inhibitor of the S protein to prevent fusogenic entry of the virus on cell lines expressing TMPRSS2.
Peptides that block either binding and fusion can be combined to make multi-functional inhibitory inactosomes.
In Aim 1, we will develop and characterize SARS-CoV-2 inactosomes that prevent endocytosis-
mediated entry into cells. In Aim 2, we will develop and characterize the SARS-CoV-2 inactosomes that
block fusogenic entry, followed by inactosomes which possess both ACE2 blocking peptides and anti-
fusogenic peptides. Combinations of SARS-CoV-2 reporter particles (bearing an eGFP gene) and SARS-CoV-2
inactosomes will be incubated in a co-culture to assess the binding and infection into 293T, Vero A6, and Calu-
3 cells. This assay will be used to optimize the chemical composition of inactosomes (type of virus binding motif,
nanoparticle structure, total protein density, ratio of virus binding motifs to fusion inhibitory motifs) to minimize
the entry of SARS-CoV-2. The optimized inactosome formulations will then be tested for inhibiting infection of
live SARS-CoV-2 virus into cells at the Penn Center for Precision Medicine.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Controlling the upstream migration of neutrophils by manipulating the function of Mac-1 and LFA-1
-
批准号:10446740
-
项目类别:
-
资助金额:$31.09万
-
财政年份:2022
-
负责人:Daniel A Hammer
-
依托单位:
Functionalized lipid inactosomes to bind and clear SARS-CoV-2
-
批准号:10370745
-
项目类别:
-
资助金额:$24.1万
-
财政年份:2022
-
负责人:Daniel A Hammer
-
依托单位:
Controlling the upstream migration of neutrophils by manipulating the function of Mac-1 and LFA-1
-
批准号:10616779
-
项目类别:
-
资助金额:$31.13万
-
财政年份:2022
-
负责人:Daniel A Hammer
-
依托单位:
Controlling the Upstream Migration of Neutrophils through the Modulation of Mac-1
-
批准号:9756062
-
项目类别:
-
资助金额:$23.81万
-
财政年份:2019
-
负责人:Daniel A Hammer
-
依托单位:
The mechanochemical control of T-cell directional migration under flow
-
批准号:9288617
-
项目类别:
-
资助金额:$41.69万
-
财政年份:2017
-
负责人:Daniel A Hammer
-
依托单位:
The mechanochemical control of T-cell directional migration under flow
-
批准号:9752590
-
项目类别:
-
资助金额:$43.31万
-
财政年份:2017
-
负责人:Daniel A Hammer
-
依托单位:
Using micropost arrays to measure traction forces during dendritic cell motility
-
批准号:8583289
-
项目类别:
-
资助金额:$35.24万
-
财政年份:2013
-
负责人:Daniel A Hammer
-
依托单位:
Using micropost arrays to measure traction forces during dendritic cell motility
-
批准号:9058548
-
项目类别:
-
资助金额:$33.74万
-
财政年份:2013
-
负责人:Daniel A Hammer
-
依托单位:
Mechano-dynamics of the Transition to Firm Adhesion and MoIotility in Neutrophils
-
批准号:8006825
-
项目类别:
-
资助金额:$23.69万
-
财政年份:2010
-
负责人:Daniel A Hammer
-
依托单位:
Integrated Multi-scale Adhesive Dynamics Modeling of T-lymphocyte Homing
-
批准号:9230321
-
项目类别:
-
资助金额:$41.72万
-
财政年份:2009
-
负责人:Daniel A Hammer
-
依托单位:
Integrated Multi-scale Adhesive Dynamics Modeling of T-lymphocyte Homing
-
批准号:8635275
-
项目类别:
-
资助金额:$42.39万
-
财政年份:2009
-
负责人:Daniel A Hammer
-
依托单位:
Simulation of Lymphocyte Adhesion using Integrated Adhesive Dynamics
-
批准号:7895491
-
项目类别:
-
资助金额:$38.56万
-
财政年份:2009
-
负责人:Daniel A Hammer
-
依托单位:
Simulation of Lymphocyte Adhesion using Integrated Adhesive Dynamics
-
批准号:7635401
-
项目类别:
-
资助金额:$37.71万
-
财政年份:2009
-
负责人:Daniel A Hammer
-
依托单位:
Integrated Multi-scale Adhesive Dynamics Modeling of T-lymphocyte Homing
-
批准号:8803240
-
项目类别:
-
资助金额:$42.17万
-
财政年份:2009
-
负责人:Daniel A Hammer
-
依托单位:
Integrated Multi-scale Adhesive Dynamics Modeling of T-lymphocyte Homing
-
批准号:8438798
-
项目类别:
-
资助金额:$40.05万
-
财政年份:2009
-
负责人:Daniel A Hammer
-
依托单位:
Force Microscopy of Endothelial Cells on Novel Peptide Materials
-
批准号:7799777
-
项目类别:
-
资助金额:$43.49万
-
财政年份:2007
-
负责人:Daniel A Hammer
-
依托单位:
Force Microscopy of Endothelial Cells on Novel Peptide Materials
-
批准号:7603047
-
项目类别:
-
资助金额:$43.08万
-
财政年份:2007
-
负责人:Daniel A Hammer
-
依托单位:
Force Microscopy of Endothelial Cells on Novel Peptide Materials
-
批准号:7265784
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2007
-
负责人:Daniel A Hammer
-
依托单位:
Force Microscopy of Endothelial Cells on Novel Peptide Materials
-
批准号:7405405
-
项目类别:
-
资助金额:$41.83万
-
财政年份:2007
-
负责人:Daniel A Hammer
-
依托单位:
Blood Systems Biology
-
批准号:7478002
-
项目类别:
-
资助金额:$26.42万
-
财政年份:2006
-
负责人:Daniel A Hammer
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
-
批准号:JCZRLH202600625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
-
批准号:2026JJ50619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:翁春艳
-
依托单位:
AURKA介导ACE2磷酸化修饰调控内皮细胞衰老在低氧性肺动脉高压中的作用及机制研究
-
批准号:82570085
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:沈慧
-
依托单位:
牛蒡叶倍半萜成分群激活ACE2/Ang1-7/MasR轴调控血管内皮—周细胞互作促缺血性脑卒中血管正常化机制研究
-
批准号:82404910
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2024
-
负责人:郝单丽
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
ACE2通过AMPK/SIRT3调控线粒体代谢改善盐敏感性高血压肾脏纤维化的机制
-
批准号:82460087
-
项目类别:地区科学基金项目
-
资助金额:33.00万元
-
批准年份:2024
-
负责人:赵宇
-
依托单位:
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
-
批准号:Y24H280055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:颜美秋
-
依托单位:
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
-
批准号:82330111
-
项目类别:重点项目
-
资助金额:220万元
-
批准年份:2023
-
负责人:刘刚
-
依托单位:
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
-
批准号:82373169
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:顾良友
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
-
批准号:32300137
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈静
-
依托单位: